Thymogen Peptide 20mg

Description

What Is Thymogen?

Thymogen is a synthetic dipeptide bioregulator with the amino acid sequence Glu-Trp (EW), developed by Professor Vladimir Khavinson at the St. Petersburg Institute of Bioregulation and Gerontology. Thymogen targets thymic tissue and immune system function, serving as a thymus bioregulator that tunes gene expression patterns in T-lymphocytes and thymic epithelial cells. It is one of the earliest and most extensively studied compounds in the Khavinson bioregulator peptides program, with published research spanning immune mixing, anti-tumor immune surveillance, and thymic involution reversal in lab and clinical gerontology settings.

Thymogen should be distinguished from thymogen alpha 1 (Thymosin Alpha-1, Thymalfasin), a 28-amino acid peptide derived from prothymosin alpha that is an approved pharmaceutical in some countries for hepatitis B and immunodeficiency conditions. While both compounds target immune function, they differ largely in cell-level weight, sequence, mechanism, and control status. Thymogen (EW dipeptide) operates through the Khavinson epigenetic bioregulation mechanism — tuning transcription through peptide-DNA interaction — while Thymosin Alpha-1 acts through direct T-cell start and toll-like receptor signaling. PrymaLab Thymogen 20mg is supplied exclusively for lab research.

Thymogen 20mg: Key Specifications

How Thymogen Works: Bioregulator Mechanism of Action

Thymogen operates through the Khavinson bioregulation mechanism — direct interaction with paired DNA sequences in the promoter regions of immune-related genes. The EW dipeptide targets gene clusters governing T-lymphocyte differentiation, thymic epithelial cell function, and immune surveillance pathways.

Thymic Gene Expression and Immune Reconstitution

The thymus undergoes progressive involution with aging, resulting in reduced naïve T-cell output, contracted T-cell receptor diversity, and impaired adaptive immune responses. Thymogen has been studied for its capacity to tune thymic epithelial cell gene expression, possibly slowing or partially reversing the transcriptional changes linked with thymic involution. Published research from the Khavinson group shows that thymogen use in aged animal models was linked with improved thymic tissue architecture markers and enhanced T-lymphocyte maturation indices.

T-Lymphocyte Differentiation and Function

Beyond thymic tissue effects, thymogen has been studied for direct tuning of T-cell gene expression profiles, including genes governing T-helper cell differentiation (Th1/Th2 balance), cytotoxic T-cell start, and control T-cell function. In immunosenescence models, thymogen use was linked with improved T-cell proliferative responses to mitogenic boost and normalization of CD4+/CD8+ T-cell ratios that become dysregulated during immune aging.

Anti-tumor Immune Surveillance

A major area of thymogen research examines its effects on anti-tumor immune surveillance. Age-related decline in T-cell function reduces the immune system’s capacity to detect and remove transformed cells, adding to increased cancer incidence with aging. Lab studies have examined thymogen’s effects on natural killer (NK) cell activity, cytotoxic T-lymphocyte (CTL) function, and tumor-specific immune response generation in aged animal models bearing experimental tumors.

Thymogen Research Applications: What Preclinical Studies Show

The following reflects published lab and clinical gerontology literature. PrymaLab Thymogen 20mg is supplied exclusively for research purposes.

Immunosenescence and Immune Aging

Thymogen is among the most extensively studied Khavinson bioregulators for immunosenescence — the progressive decline of immune function with aging. Published data shows effects on T-cell proliferative capacity, cytokine production profiles, thymic architecture preservation, and immune response quality in aged animal models. Khavinson’s research group has published data showing that bioregulator peptide treatment, including thymogen, was linked with improved immune function parameters and reduced age-related immune dysfunction markers in elderly cohorts in gerontological studies.

Cancer Research Support

Lab studies have examined thymogen’s role as an adjunct in cancer immunology research, focusing on its capacity to enhance anti-tumor immune responses through T-cell and NK cell start. Published animal studies documented improved tumor immune surveillance markers and reduced tumor growth rates in aged animals treated with thymic bioregulator peptides compared to untreated age-matched controls. These findings are of research interest in the context of immuno-oncology and age-related cancer susceptibility.

Infectious Disease Resistance

Age-related immune decline increases susceptibility to infectious diseases, and thymogen has been studied for its effects on immune defense capacity against bacterial and viral challenge models. Published data shows improved immune response kinetics and enhanced pathogen clearance in bioregulator-treated aged animals, consistent with restored T-cell functional competence.

Thymogen vs. Thymogen Alpha-1 (Thymosin Alpha-1): Key Differences

How to Store and Handle PrymaLab Thymogen 20mg

1. Store freeze-dried at −20°C. Keep sealed, desiccated, and protected from light. Stable for 24+ months.
2. Allow vial to reach room heat before opening to prevent condensation.
3. Reconstitute with appropriate sterile solvent. Add slowly along vial wall.
4. Use mixed solution within 2–4 weeks. Refrigerate at 2–8°C.
5. Avoid repeated freeze-thaw cycles. Aliquot into single-use portions.
6. Retain the Certificate of Test for lot traceability.

Why Choose PrymaLab Thymogen 20mg?

PrymaLab supplies Thymogen 20mg as a high-purity research-grade bioregulator peptide verified at ≥98% purity by reverse-phase HPLC and identity-confirmed by mass spectrometry. Each batch ships with a unique lot number and Certificate of Test. Independent third-party testing ensures unbiased quality check and full traceability.

Frequently Asked Questions About Thymogen

What is thymogen and how does it differ from thymogen alpha 1?

Thymogen is a synthetic dipeptide (Glu-Trp, EW) from the Khavinson bioregulator program that targets thymic and immune tissue through epigenetic gene expression tuning. Thymogen alpha 1 (Thymalfasin/Zadaxin) is a separate 28-amino acid peptide that acts through direct T-cell start and TLR signaling. They differ in size (2 vs 28 amino acids), mechanism, and control status. Thymogen is a research compound; Thymosin Alpha-1 is an approved pharmaceutical in some countries.

What are thymogen’s primary research applications?

Thymogen has been studied in immunosenescence (immune aging) models, anti-tumor immune surveillance research, infectious disease resistance, and thymic involution reversal. Research areas include T-lymphocyte differentiation and function, NK cell activity boost, and normalization of age-related immune dysregulation. All uses are in lab research settings.

Can thymogen be combined with other bioregulator peptides?

Published Khavinson research protocols have used thymogen alongside other bioregulator peptides targeting different organ systems. As an immune-specific bioregulator, thymogen is most often studied in mix with organ-specific bioregulators when researchers are studying full multi-system anti-aging protocols involving simultaneous immune support and target organ bioregulation.

How is thymogen stored?

Store freeze-dried thymogen at −20°C, desiccated and protected from light, for 24+ months shelf life. After mixing, refrigerate at 2–8°C and use within 2–4 weeks. Aliquot to avoid freeze-thaw cycles.

What testing does PrymaLab perform?

Every batch is verified at ≥98% purity by reverse-phase HPLC and identity-confirmed by mass spectrometry. Independent third-party testing with batch-specific Certificate of Test ensures unbiased quality check and full traceability.

Research Disclaimer

For Research Use Only. PrymaLab Thymogen 20mg is intended exclusively for qualified lab research use. This product is not intended for human consumption, treatment use, veterinary treatment, or any use outside controlled research environments. Thymogen (EW dipeptide) has not been approved by the FDA or any equivalent control authority for treatment use. All research uses described are from published lab and gerontological literature. Researchers are responsible for control compliance.